One shot for boys could slash HPV in tanzania

NCT ID NCT04953130

Ongoing Prevention Sponsor: London School of Hygiene and Tropical Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study in Tanzania tests whether giving boys a single dose of the HPV vaccine (Gardasil) can lower HPV infections in the community. Over 10,000 participants in 26 communities will be split: some communities vaccinate only girls (as usual), while others also vaccinate boys aged 14-18. After 3 years, researchers will compare HPV rates in young adults to see if adding boys makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gardasil® HPV vaccine (4-valent)
What this could lead to: If successful, this could show that vaccinating boys with a single dose helps reduce HPV infections in the whole community, supporting broader vaccination programs.
What could go wrong: This is a large trial but results depend on community participation and follow-up. The single-dose approach may not provide long-lasting protection, and the study only measures impact after 3 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Vaccine-Preventable Diseases human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV INFECTION VACCINE PREVENTABLE DISEASE

Contacts and locations

Locations

Mwanza Intervention Trials Unit

Mwanza, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.